Reduces proteinuria. Sold as Vanrafia. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Atrasentan Hydrochloride (sold as Vanrafia), first approved Apr 2, 2025, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Vanrafia | Part D | $3.2M | New | 71 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANBerger Disease, Bergers Disease · Novartis Pharmaceuticals | Phase 3 | Recruiting | Mar 27, 2026 |
| Atrasentan in Patients With IgA NephropathyIgA Nephropathy, Immunoglobulin A Nephropathy · Novartis Pharmaceuticals | Phase 3 | Active, not recruiting | Oct 5, 2020 |
| Atrasentan in Patients With Proteinuric Glomerular DiseasesIgA Nephropathy, Focal Segmental Glomerulosclerosis · Novartis Pharmaceuticals | Phase 2 | Active, not recruiting | Oct 5, 2020 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis